World Investment Advisors Invests $1.66 Million in Guardant Health, Inc. $GH

World Investment Advisors bought a new position in shares of Guardant Health, Inc. (NASDAQ:GH) during the 4th quarter, Holdings Channel reports. The firm bought 16,290 shares of the company’s stock, valued at approximately $1,664,000.

Several other hedge funds have also added to or reduced their stakes in the company. F m Investments LLC boosted its holdings in Guardant Health by 24.1% in the fourth quarter. F m Investments LLC now owns 58,567 shares of the company’s stock valued at $5,982,000 after acquiring an additional 11,363 shares during the last quarter. Ethic Inc. boosted its holdings in Guardant Health by 39.0% in the fourth quarter. Ethic Inc. now owns 5,358 shares of the company’s stock valued at $547,000 after acquiring an additional 1,503 shares during the last quarter. Wesbanco Bank Inc. bought a new position in Guardant Health in the fourth quarter valued at about $308,000. Wulff Hansen & CO. bought a new position in Guardant Health in the fourth quarter valued at about $325,000. Finally, Ascent Wealth Partners LLC bought a new position in Guardant Health in the fourth quarter valued at about $253,000. Institutional investors own 92.60% of the company’s stock.

Wall Street Analyst Weigh In

GH has been the topic of several recent research reports. Leerink Partners raised their price target on Guardant Health from $170.00 to $180.00 and gave the company an “outperform” rating in a report on Friday, February 20th. Barclays raised their price target on Guardant Health from $115.00 to $120.00 and gave the company an “overweight” rating in a report on Friday, May 8th. JPMorgan Chase & Co. raised their price target on Guardant Health from $130.00 to $135.00 and gave the company an “overweight” rating in a report on Friday, May 8th. Robert W. Baird initiated coverage on Guardant Health in a report on Tuesday, February 17th. They issued an “outperform” rating and a $120.00 price target on the stock. Finally, Canaccord Genuity Group raised their price target on Guardant Health from $125.00 to $135.00 and gave the company a “buy” rating in a report on Friday, February 20th. Nineteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $129.42.

Guardant Health Trading Down 3.8%

NASDAQ:GH opened at $94.92 on Friday. Guardant Health, Inc. has a 1-year low of $36.36 and a 1-year high of $120.74. The business’s 50-day moving average price is $89.30 and its two-hundred day moving average price is $97.90. The firm has a market capitalization of $12.59 billion, a price-to-earnings ratio of -28.00 and a beta of 1.48.

Guardant Health (NASDAQ:GH) last released its earnings results on Thursday, February 19th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.07). The business had revenue of $281.27 million during the quarter, compared to analysts’ expectations of $269.74 million. During the same quarter last year, the firm earned ($0.62) earnings per share. The company’s revenue for the quarter was up 39.4% on a year-over-year basis. Sell-side analysts predict that Guardant Health, Inc. will post -2.87 earnings per share for the current year.

Insider Activity at Guardant Health

In other news, CFO Michael Brian Bell sold 3,000 shares of the firm’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $87.04, for a total transaction of $261,120.00. Following the sale, the chief financial officer owned 43,601 shares of the company’s stock, valued at $3,795,031.04. This trade represents a 6.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Medina Manuel Hidalgo sold 1,300 shares of the firm’s stock in a transaction dated Friday, March 6th. The stock was sold at an average price of $91.54, for a total value of $119,002.00. Following the sale, the director directly owned 1,193 shares in the company, valued at approximately $109,207.22. This represents a 52.15% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 58,596 shares of company stock valued at $5,791,767 over the last 90 days. Insiders own 5.60% of the company’s stock.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.